Literature DB >> 27927036

Integrative group-based cognitive rehabilitation efficacy in multiple sclerosis: a randomized clinical trial.

Oiane Rilo1, Javier Peña1, Natalia Ojeda1, Alfredo Rodríguez-Antigüedad2, Mar Mendibe-Bilbao3, Ainara Gómez-Gastiasoro1, John DeLuca4,5, Nancy Chiaravalloti4,5, Naroa Ibarretxe-Bilbao1.   

Abstract

PURPOSE: This study aimed to determine the efficacy of the integrative group-based cognitive rehabilitation programme, REHACOP, on improving cognitive functions in multiple sclerosis (MS).
METHODS: Fourty-two MS patients were randomized to the treatment programme REHACOP (n = 21) or waiting list control condition (n = 21). The REHACOP group received cognitive rehabilitation in group format for three months focused on attention, processing speed, learning and memory, language, executive functioning, and social cognition. Patients completed a neuropsychological assessment at baseline and follow-up, which included tests of attention, processing speed, working memory, verbal memory, verbal fluency, and executive functioning. Repeated measures multivariate analysis of covariance (MANCOVA) was used to determine the efficacy of the cognitive rehabilitation programme.
RESULTS: Group × Time interactions revealed significant improvements in the REHACOP group as compared with the control group for processing speed (p = 0.011, np2 = 0.16), working memory (p = 0.014, np2 = 0.15), verbal memory (p = 0.025, np2 = 0.13), and executive functioning (p = 0.024, np2 = 0.13), showing medium-large effect sizes.
CONCLUSIONS: Patients receiving REHACOP showed improvements in several cognitive domains. This preliminary study thus provides evidence supporting the efficacy of this integrative group-based cognitive rehabilitation intervention in MS. Future research should confirm these findings, examine the impact of the treatment on everyday life functioning and explore the presence of brain changes associated with cognitive rehabilitation. Implications for rehabilitation This study provides initial evidence for integrative group-based cognitive rehabilitation efficacy in MS patients through the implementation of the REHACOP cognitive rehabilitation programme. Patients received cognitive rehabilitation for three months (3 one-hour-sessions per week) focused on training attention, learning and memory, language, executive functioning, and social cognition. Patients attending REHACOP sessions showed medium to large and statistically significant improvements in processing speed, working memory, verbal memory, and executive functioning.

Entities:  

Keywords:  REHACOP; cognition; multiple sclerosis; neurodegenerative diseases; neuropsychological rehabilitation

Mesh:

Year:  2016        PMID: 27927036     DOI: 10.1080/09638288.2016.1250168

Source DB:  PubMed          Journal:  Disabil Rehabil        ISSN: 0963-8288            Impact factor:   3.033


  14 in total

1.  Group cognitive rehabilitation to reduce the psychological impact of multiple sclerosis on quality of life: the CRAMMS RCT.

Authors:  Nadina B Lincoln; Lucy E Bradshaw; Cris S Constantinescu; Florence Day; Avril Er Drummond; Deborah Fitzsimmons; Shaun Harris; Alan A Montgomery; Roshan das Nair
Journal:  Health Technol Assess       Date:  2020-01       Impact factor: 4.014

2.  Integrated Cognitive Rehabilitation Home-Based Protocol to Improve Cognitive Functions in Multiple Sclerosis Patients: A Randomized Controlled Study.

Authors:  Minoo Sharbafshaaer; Francesca Trojsi; Simona Bonavita; Amirreza Azimi
Journal:  J Clin Med       Date:  2022-06-20       Impact factor: 4.964

Review 3.  Memory rehabilitation for people with multiple sclerosis.

Authors:  Lauren A Taylor; Jacqueline R Mhizha-Murira; Laura Smith; Kristy-Jane Potter; Dana Wong; Nikos Evangelou; Nadina B Lincoln; Roshan das Nair
Journal:  Cochrane Database Syst Rev       Date:  2021-10-18

Review 4.  Cognitive Deficits in Multiple Sclerosis: Recent Advances in Treatment and Neurorehabilitation.

Authors:  Arseny A Sokolov; Petr Grivaz; Riley Bove
Journal:  Curr Treat Options Neurol       Date:  2018-10-22       Impact factor: 3.598

5.  A network-based cognitive training induces cognitive improvements and neuroplastic changes in patients with relapsing-remitting multiple sclerosis: an exploratory case-control study.

Authors:  Riccardo Manca; Micaela Mitolo; Iain D Wilkinson; David Paling; Basil Sharrack; Annalena Venneri
Journal:  Neural Regen Res       Date:  2021-06       Impact factor: 5.135

6.  Focus on neglected features of cognitive rehabilitation in MS: Setting and mode of the treatment.

Authors:  Jessica Podda; Andrea Tacchino; Ludovico Pedullà; Margherita Monti Bragadin; Mario Alberto Battaglia; Giampaolo Brichetto
Journal:  Mult Scler       Date:  2020-10-13       Impact factor: 5.855

7.  Functional training is a senseless strategy in MS cognitive rehabilitation: Strategy training is the only useful approach - NO.

Authors:  Hanneke E Hulst; Dawn W Langdon
Journal:  Mult Scler       Date:  2017-03-23       Impact factor: 6.312

8.  Study protocol: improving cognition in people with progressive multiple sclerosis: a multi-arm, randomized, blinded, sham-controlled trial of cognitive rehabilitation and aerobic exercise (COGEx).

Authors:  Anthony Feinstein; Maria Pia Amato; Giampaolo Brichetto; Jeremy Chataway; Nancy Chiaravalloti; Ulrik Dalgas; John DeLuca; Peter Feys; Massimo Filippi; Jennifer Freeman; Cecilia Meza; Matilde Inglese; Robert W Motl; Maria Assunta Rocca; Brian M Sandroff; Amber Salter; Gary Cutter
Journal:  BMC Neurol       Date:  2020-05-22       Impact factor: 2.474

Review 9.  Treatment and management of cognitive dysfunction in patients with multiple sclerosis.

Authors:  John DeLuca; Nancy D Chiaravalloti; Brian M Sandroff
Journal:  Nat Rev Neurol       Date:  2020-05-05       Impact factor: 42.937

10.  Face-to-Face or Telematic Cognitive Stimulation in Patients with Multiple Sclerosis and Cognitive Impairment: Why Not Both?

Authors:  C Guijarro-Castro; Y Aladro-Benito; A Sánchez-Musulim; A Belen-Caminero; I Pérez Molina; I Gómez-Moreno; L Gómez-Romero; J Millán-Pascual; M J Laredo; M Cerezo-García
Journal:  Behav Neurol       Date:  2017-12-13       Impact factor: 3.342

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.